Natural Product (NP) Details
General Information of the NP (ID: NP1928) | |||||
---|---|---|---|---|---|
Name |
Carnosic acid
|
||||
Synonyms |
Salvin; UNII-LI791SXT24; LI791SXT24; CHEBI:65585; 11,12-dihydroxyabieta-8,11,13-trien-20-oic acid; MFCD02259459; NSC694080; (4aR,10aS)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-4a-carboxylic Acid; Carnosic acid from Rosmarinus officinalis; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylic acid; 139236-75-2; RoseOx; 11,12-dihydroxy-13-isopropylpodocarpa-8,11,13-trien-17-oic acid; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2H)-carboxylic acid; Rosamox; Carnosic-acid; Carsonic acid; Carnosic acid; Deoxypicrosalvinic acid; PubChem13039; UPCMLD-DP056; CHEMBL484853; SCHEMBL9923661; UPCMLD-DP056:001; DTXSID20904450; BCPP000299; Carnosic acid, analytical standard; HY-N0644; ZINC3984016; ANW-43614; BDBM50371232; s3838; AKOS015901362; AC-6030; BCP9000491; CCG-207954; NSC-694080; SMP2_000204; NCGC00161623-01; 4a(2H)-Phenanthrenecarboxylic acid, 1,3,4,9,10,10a-hexahydro-5,6-dihydroxy-1,1-dimethyl-7-(1-methylethyl)-, (4aR-trans)-; AS-31052; NCI60_033653; P527; BCP0726000155; C3477; CS-0009671; N2759; C21818; 650C097; Q412827; SR-05000002202; SR-05000002202-2; Carnosic acid, primary pharmaceutical reference standard; Carnosic acid from Rosmarinus officinalis, >=91%, powder; Carnosic acid, United States Pharmacopeia (USP) Reference Standard; Podocarpa-8,11,13-trien-17-oic acid, 11,12-dihydroxy-13-isopropyl-
Click to Show/Hide
|
||||
Species Origin | Salvia rosmarinus ... | Click to Show/Hide | |||
Salvia rosmarinus | |||||
Disease | Cervical cancer [ICD-11: 2C77] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C20H28O4
|
||||
PubChem CID | |||||
Canonical SMILES |
CC(C)C1=C(C(=C2C(=C1)CCC3C2(CCCC3(C)C)C(=O)O)O)O
|
||||
InChI |
1S/C20H28O4/c1-11(2)13-10-12-6-7-14-19(3,4)8-5-9-20(14,18(23)24)15(12)17(22)16(13)21/h10-11,14,21-22H,5-9H2,1-4H3,(H,23,24)/t14-,20+/m0/s1
|
||||
InChIKey |
QRYRORQUOLYVBU-VBKZILBWSA-N
|
||||
CAS Number |
CAS 3650-09-7
|
||||
Herb ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | ARG1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CD178 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | GZMB | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | IFNG | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PRF1 | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Mouse LLC (Lewis lung cancer) cells (5*106 cells in 0.1 mL) were injected into the right flank of C57BL/6 mice. | |||||
Experimental
Result(s) |
Carnosic acid enhances the anti-lung cancer effect of cisplatin by inhibiting myeloid-derived suppressor cells. | |||||
Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | |||
Experimental
Result(s) |
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma. | |||||
Tamoxifen | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TNFRSF10C | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TNFRSF10D | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TNFSF10 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TP73 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
T-47D | CVCL_0553 | Invasive breast carcinoma | Homo sapiens | |||
In-vivo Model | 5*105 MCF-7 cells were subcutaneously injected into the dorsal flanks of athymic nude mice. | |||||
Experimental
Result(s) |
Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo. | |||||
1,25-dihydroxyvitamin D3 | Congenital alopecia | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Phosphorylation | c-RAF | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | MEK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | RSK1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
Experimental
Result(s) |
Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. | |||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BBC3 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells. |